Bluejay Diagnostics (BJDX) Total Debt (2020 - 2021)

Bluejay Diagnostics (BJDX) reported Total Debt of $12000.0 for Q4 2021, down 90.41% on a YoY basis from $125102.0 in Q4 2020, and down 90.41% sequentially from $125102.0 in Q3 2021.

Bluejay Diagnostics (BJDX) Total Debt (2020 - 2021) Analysis & Trends

Bluejay Diagnostics (BJDX) has 2 years of Total Debt data on file, last reported at $12000.0 in Q4 2021.

  • For the quarter ending Q4 2021, Total Debt fell 90.41% year-over-year to $12000.0; the trailing twelve-month figure through Dec 2021 stood at $12000.0 (down 90.41% YoY), and the FY2021 full-year result was $12000.0, down 90.41% from the prior year.
  • Total Debt retreated to $12000.0 in Q4 2021, from $125102.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $125102.0 in Q4 2020 to a low of $12000.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 34.05 Bn
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 14.72 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 27.96 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 11.03 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 598.50 Mn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn -
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 9.48 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 10.14 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 3.18 Bn
10 Bluejay Diagnostics 2,754.24 2,754.24 - -

Historic Data

Download Data
DateValue
Dec 31, 2021 12,000.00
Sep 30, 2021 125,102.00
Dec 31, 2020 125,102.00